Haemonetics (NYSE: HAE) announced today that it acquired percutaneous vessel closure device maker Vivasure Medical.

Investors may be wondering whether Haemonetics at around US$74 is offering value right now, or whether the market is still undecided about its future potential. The stock has been quite mixed lately, ...

Vivasure Medical Limited (“Vivasure”) has been a strategic holding of Orchestra BioMed since the Company’s formation NEW HOPE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc.

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.

Why Haemonetics’ Price Target Just Nudged Higher Haemonetics’ fair value estimate has been nudged higher from about US$90.20 ...

Haemonetics has acquired Vivasure, an Ireland-based company developing next-generation technology for percutaneous vessel ...

Analysts have recently evaluated Haemonetics and provided 12-month price targets. The average target is $87.45, accompanied ...

Haemonetics' acquisition of Vivasure adds PerQseal Elite, advancing large-bore closure solutions for TAVR and EVAR markets.

Orchestra BioMed (Nasdaq:OBIO) expects to receive up to $21 million in cash as a result of Haemonetics' recent.

Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential milestone payments.

BOSTON, Oct. 6, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, ...